Clinical Trial Update: Anti-Interleukin-5 Antibody to Treat Hypereosinophilic Syndrome [Phase 2]

View source ↗

Summary

A Phase 2 trial of an anti-Interleukin-5 antibody for hypereosinophilic syndrome has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypereosinophilic Syndrome

Drugs mentioned

• Anti-Interleukin-5 Antibody

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Hypereosinophilic Syndrome | Phase 2 | Status: COMPLETED